Navigating SGLT2 Inhibitors and GLP-1 Agonists Use in the Older Adult: A Guide to Benefits, Risks, and Shared Decision-Making

All sessions are listed in Eastern Standard Time (EST). 

Symposia

  • Date:
  • Time: -
  • Track: Clinical Practice
  • CME/CE: 1.0

Sponsored by the Research Committee and the Clinical Practice & Models of Care Committee and the Older Adults Facing Chronic Kidney Disease and/or Kidney Failure Special Interest Group

Moderator: Totini S. Chatterjee, MD

This symposium will address the professional practice gap in the practice of prescribing and management of SGLT2 inhibitors and GLP-1 agonists in older adults with chronic kidney disease and geriatric syndromes. Learning Objectives: (1) review the evidence for the use of for the use of SGLT2 inhibitors and/or GLP-1 agonists in older and multimorbid adults, including a focus on historically underserved populations. Changes in clinical guidelines from various professional societies will be included; (2) discuss notable adverse effects associated with the SGLT2 inhibitors and GLP-1 agonists, emphasizing their impact on geriatric syndromes; and (3) using an age-friendly “5M” framework, discuss when SGLT2 inhibitors and/or GLP-1 agonists should be used or deprescribed.

Use of SGLT2 Inhibitors and GLP-1 Agonists in the Older Adult: The Next Frontier
Daniel Forman, MD

SGLT2 Inhibitors and GLP-1 Agonists: Key Considerations in the Older Adult
Chintan V. Dave, PharmD, PhD

What Matters Most: Applying the 5M Framework
Onica L. Washington, MD, PhD